1,204 karma · joined June 15, 2014
This summarizes the evidence nicely: https://en.wikipedia.org/wiki/Younger_Dryas_impact_hypothesi...
the weird and new part is that the people cornering the market are a horde of retail traders who are colluding in the open, but in a way regulators probably don't have tools to address.
The share has been lent twice.
There is one share, and Ellen owns it for real.
Everyone else has these agreements involving collateral and promises to get/give a share back.
https://journals.plos.org/plosone/article?id=10.1371/journal...
It's a crude, bulky, ugly, and fragile thing and the $1 price is not realistic - but it would be less than $10. It seems like a decent product for the poorest places - which is their goal.
The hearing aid biz in the US is glaringly inefficient and obviously ripe for disruption - but this product will not do it here. There's definitely a demand for hearing aids in the couple-of-hundred dollar range that doesn't require audiologist visits and insurance hassle - but the entrenched interests will not help bring it about.
last item, heading is "Reserve Requirements"
"... the Board has reduced reserve requirement ratios to zero percent effective on March 26"
I've moved to Trio over asyncio (I did plain old async for a couple years and Trio makes a ton of sense)
Quart-trio over Flask (just to get a Trio-friendly flask-a-like server) - plain old aiohttp worked really well too. It takes a bit more roll-your-own work, but you get exactly what you want.
peewee over SQLAlchemy (less committed to this change, but peewee has been fine so far and is much more streamlined) I'm mostly just using SQLite. the async version of the ORM looks pretty new, i'm not using it yet.